tradingkey.logo
tradingkey.logo
Search

Merck jumps as lab demand lifts 2026 outlook

ReutersMay 13, 2026 6:35 AM
facebooktwitterlinkedin
View all comments0

Germany's Merck MRCG.DE is up 4.4% in early Frankfurt trade after it raised its full-year guidance on stronger demand for its lab supplies and delayed competition for its Mavenclad multiple sclerosis drug

The science and healthcare firm also reported higher-than-expected Q1 EBITDA of 1.53 billion euros, beating average analyst expectations of 1.46 billion euros

"Given the strong set of results and FY’26 Guidance upgrade... we expect the shares to outperform by 2-3% today," JPMorgan says

The stock is at the top of German blue-chip index DAX .GDAXI in early Frankfurt trade

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Comments (0)

Click the $ button, enter the symbol, and select to link a stock, ETF, or other ticker.

0/500
Commenting Guidelines
Loading...

Recommended Articles

Tradingkey
KeyAI